Drug Profile
Research programme: interferon beta gene therapy - Bayer HealthCare Pharmaceuticals
Latest Information Update: 24 Mar 2010
Price :
$50
*
At a glance
- Originator Berlex Biosciences
- Developer Bayer HealthCare Pharmaceuticals
- Class Gene therapies
- Mechanism of Action Interferon beta stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 10 Oct 2008 Preclinical development is ongoing in USA
- 04 Apr 2007 Berlex is now called Bayer HealthCare Pharmaceuticals
- 20 Jun 2005 Preclinical trials in Multiple sclerosis in USA (IM)